A Phase 3, Randomized, Double-blind, Active-controlled Study to Evaluate the Effects of Bexagliflozin versus Glimepiride in Subjects with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control by Metformin.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 08 Sep 2017
At a glance
- Drugs Bexagliflozin (Primary) ; Glimepiride
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Theracos
- 01 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated
- 09 Mar 2017 Planned primary completion date changed from 1 Aug 2019 to 1 Jun 2019.